Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Blood

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Blood|November 21, 2015
Is there a best TKI for chronic phase CML?Richard A Larson
Blood|June 12, 2010
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigmRoland B Walter, Frederick R Appelbaum, Martin S Tallman, et al.
Blood|August 17, 2004
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628Madhav V Dhodapkar, Mohamad A Hussein, Erik Rasmussen, et al.
Blood|May 27, 2008
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesWendy Stock, Mei La, Ben Sanford, et al.
Blood|February 8, 2008
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyRichard A Larson, Brian J Druker, Francois Guilhot, et al.
Blood|April 22, 2006
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trialsLydia Roy, Joëlle Guilhot, Tillmann Krahnke, et al.
Blood|February 1, 2007
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511Meir Wetzler, Ben L Sanford, Joanne Kurtzberg, et al.
Blood|April 23, 2008
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibilityNathan A Ellis, Dezheng Huo, Ozlem Yildiz, et al.
Blood|March 8, 2003
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesSonali M Smith, Michelle M Le Beau, Dezheng Huo, et al.
Blood|October 24, 2002
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)John C Byrd, Bercedis L Peterson, Vicki A Morrison, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Blood|November 21, 2015
Is there a best TKI for chronic phase CML?Richard A Larson
Blood|June 12, 2010
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigmRoland B Walter, Frederick R Appelbaum, Martin S Tallman, et al.
Blood|August 17, 2004
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628Madhav V Dhodapkar, Mohamad A Hussein, Erik Rasmussen, et al.
Blood|May 27, 2008
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesWendy Stock, Mei La, Ben Sanford, et al.
Blood|February 8, 2008
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyRichard A Larson, Brian J Druker, Francois Guilhot, et al.
Blood|April 22, 2006
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trialsLydia Roy, Joëlle Guilhot, Tillmann Krahnke, et al.
Blood|February 1, 2007
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511Meir Wetzler, Ben L Sanford, Joanne Kurtzberg, et al.
Blood|April 23, 2008
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibilityNathan A Ellis, Dezheng Huo, Ozlem Yildiz, et al.
Blood|March 8, 2003
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesSonali M Smith, Michelle M Le Beau, Dezheng Huo, et al.
Blood|October 24, 2002
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)John C Byrd, Bercedis L Peterson, Vicki A Morrison, et al.
Pageof 7